Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher inpatient morbidity and longer hospital stay compared with RP for nonmetastatic PCa, investigators reported at the 34th Annual European Association of Urology Congress in Barcelona, Spain.
Sohrab Arora, MD, and colleagues from Vattikuti Urology Institute at Henry Ford Hospital in Detroit, studied 91,835 patients with PCa who underwent RP. Of these, 1173 of these had metastatic disease. A significantly higher proportion of patients in the cytoreductive RP than nonmetastatic group had inpatient complications of any type (19.1% vs 14.9%), blood transfusion (6.9% vs 4.3%), genitourinary complications (4.3% vs 2.3%), miscellaneous surgical complications (1.6% vs. 0.8%) and miscellaneous medical complications (2.5% vs. 1.6%), Dr Arora’s group reported in a poster presentation. The cytoreductive RP group had a significantly longer median length of hospital stay (1.25 vs 0.97 days).
On multivariable analysis, the presence of metastasis, compared with its absence, was independently associated with significant 1.3-fold higher odds of any complication.
In addition, cytoreductive RP was associated with significantly higher total costs compared with RP for nonmetastatic PCa ($14,123 vs $11,591).
“This information may be valuable for informed decision-making in practice and before recruiting patients in clinical trials on this subject,” the investigators concluded.
Arora S, Sood A, Dalela D, et al. Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States. Presented at the 34th Annual European Association of Urology Congress in Barcelona, Spain, March 15 to 19. Poster 1036.